Attovia Therapeutics (NASDAQ:ATTO) has arrived on public markets with a pipeline built entirely on one bet: that a biparatopic antibody platform called Attobody can turn well-validated immunology targets into next-generation biologics. The lead asset is aimed at the cytokine behind chronic itch.
Shares last changed hands at $19.86, up 3.6% on the session, giving Attovia a market capitalization of roughly $287.9 million. With only eight trading days of history, the stock has drifted 9.32% lower from its $21.90 early print.
The IL-31 Itch Thesis
The centerpiece is ATTO-1310. Per the S-1, it is a “novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31” and is currently in a Phase 1 clinical trial in healthy volunteers and patients. Attovia is developing it for chronic pruritus and high-itch atopic dermatitis, positioning against a cytokine the filing describes it thus: “IL-31 commonly known as the ‘itch cytokine.’ IL-31 upregulated in host of pruritic diseases.”
The label ambition extends to chronic pruritus of unknown origin and cholestatic pruritus in primary biliary disease.
Platform and Pipeline
Attobody was in-licensed from Alamar Biosciences and uses an evolution-driven, high-throughput process to generate biparatopic biologics. Behind ATTO-1310 sit two additional candidates:
- ATTO-2306: a bispecific targeting IL-13 and IL-31, in IND-enabling studies, with a Phase 1 trial expected to commence in the first half of 2027.
- ATTO-1091: a trispecific Attobody-based Fc fusion protein designed to block TL1A, IL-23 and integrin a4ß7 simultaneously, aimed at inflammatory bowel disease.
The company, founded in 2023, disclosed it raised $255.8 million as of March 31, 2026. That runway that included a $90 million Series C reported ahead of the offering. Underwriters on the IPO include Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets, and LifeSci Capital.
Risks the Filing Flags
Attovia is classified as an emerging growth company and smaller reporting company, meaning reduced disclosure requirements. The prospectus also cautions that revenue depends on commercial sales of ATTO-1310, ATTO-2306, ATTO-1091, or future product candidates, if approved, and that further development of the Attobody platform is required. Product liability, trial timelines, and manufacturing partnerships all appear in the risk factors.
What to Watch
The nearest-term catalysts are ATTO-1310 Phase 1 readouts in pruritus indications, followed by the ATTO-2306 IND clearance targeted for the first half of 2027. For a clinical-stage company with a newly issued float and no near-term commercial revenue, those data readouts will define whether the Attobody thesis can translate from a platform pitch into a franchise.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks